Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy
Summary: Here, we present a protocol for a preclinical ex vivo platform combining experimental flexibility with preservation of the tumor microenvironment. We outline steps for isolating human peripheral blood mononuclear cells (PBMCs), preparing patient-derived precision-cut tumor slices (PCTSs), c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | STAR Protocols |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666166725000292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206893481558016 |
|---|---|
| author | Wen-Hsin Chang Andrew I. Chin Ching-Hsien Chen |
| author_facet | Wen-Hsin Chang Andrew I. Chin Ching-Hsien Chen |
| author_sort | Wen-Hsin Chang |
| collection | DOAJ |
| description | Summary: Here, we present a protocol for a preclinical ex vivo platform combining experimental flexibility with preservation of the tumor microenvironment. We outline steps for isolating human peripheral blood mononuclear cells (PBMCs), preparing patient-derived precision-cut tumor slices (PCTSs), cryopreserving the samples, and setting up the co-culture system. We provide instructions for treatment applications, interactions, and analyzing therapy responses. By preserving tumor architecture and heterogeneity, this model is applicable for evaluating tumor characteristics, immune interactions, and treatment efficacy in translational cancer research. : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. |
| format | Article |
| id | doaj-art-ab51079be57c423890d3d1c1310e02d6 |
| institution | Kabale University |
| issn | 2666-1667 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | STAR Protocols |
| spelling | doaj-art-ab51079be57c423890d3d1c1310e02d62025-02-07T04:48:20ZengElsevierSTAR Protocols2666-16672025-03-0161103623Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacyWen-Hsin Chang0Andrew I. Chin1Ching-Hsien Chen2Division of Nephrology, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, USADivision of Nephrology, Department of Internal Medicine, University of California, Davis, Davis, CA, USADivision of Nephrology, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, USA; Corresponding authorSummary: Here, we present a protocol for a preclinical ex vivo platform combining experimental flexibility with preservation of the tumor microenvironment. We outline steps for isolating human peripheral blood mononuclear cells (PBMCs), preparing patient-derived precision-cut tumor slices (PCTSs), cryopreserving the samples, and setting up the co-culture system. We provide instructions for treatment applications, interactions, and analyzing therapy responses. By preserving tumor architecture and heterogeneity, this model is applicable for evaluating tumor characteristics, immune interactions, and treatment efficacy in translational cancer research. : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.http://www.sciencedirect.com/science/article/pii/S2666166725000292Cell BiologyCell cultureCell isolationCell-based AssaysCancerImmunology |
| spellingShingle | Wen-Hsin Chang Andrew I. Chin Ching-Hsien Chen Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy STAR Protocols Cell Biology Cell culture Cell isolation Cell-based Assays Cancer Immunology |
| title | Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy |
| title_full | Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy |
| title_fullStr | Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy |
| title_full_unstemmed | Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy |
| title_short | Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy |
| title_sort | protocol for a patient derived preclinical platform to model tumor immune interactions and evaluate therapeutic efficacy |
| topic | Cell Biology Cell culture Cell isolation Cell-based Assays Cancer Immunology |
| url | http://www.sciencedirect.com/science/article/pii/S2666166725000292 |
| work_keys_str_mv | AT wenhsinchang protocolforapatientderivedpreclinicalplatformtomodeltumorimmuneinteractionsandevaluatetherapeuticefficacy AT andrewichin protocolforapatientderivedpreclinicalplatformtomodeltumorimmuneinteractionsandevaluatetherapeuticefficacy AT chinghsienchen protocolforapatientderivedpreclinicalplatformtomodeltumorimmuneinteractionsandevaluatetherapeuticefficacy |